|
KMID : 0378019940370070080
|
|
New Medical Journal
1994 Volume.37 No. 7 p.80 ~ p.88
|
|
|
Clinical Application of Ensure Liquid in Patients with Stomach Cancer
|
|
|
|
|
Abstract
|
|
|
A prospective study was undertaken to evaluate clinical usefulness and safety of Ensure Liquid as nutritional supplement in patients with advanced gastric cancer after gastrectomy.
The patients were divided by random sampling into control group (20 cases) and Ensure group (21 cases). No significant difference was observed in background such as age, sex, disease and operation between 2 groups.
The patients in Ensure group were given Ensure orally from 3rd day after operation. Half strength (0.5 kcal/ml) of 500 kcal was administered initially. Concentration and dosage were gradually increased 500 kcal daily to reach the full strength (1 kcal/ml) and maintenance dosage (1500-2000 kcal/day).
Response, concentration, duration, feeding speed, total calorie intake, adverse effects and nutritional status after treatment were assessed. Also clinical laboratory data and duration of admission were compared between these 2 groups.
The results-were as follows
1. All patients were tolerable to oral administration.
2. Ensure was administered for 7 days in half of the patients.
3. Maintenance dosage was administered in 3 patients.
4. Full strength of concentration was tolerable in most of patients and feeding speed was determined by themselves.
5 Total lymphocyte count after treatment of Ensure group was increased significantly than that of control group (p<0.05), but the serum albumin level after treatment in Ensure group was not increased than that of control group significantly.
6. Side effects mainly diarrhea were observed in 3 cases (14%), two of them accompanied abdominal pain and abdominal distension.
7. Duration of admission in Ensure group(22.4±4.9 days) was shorter than that of control group(23.1±5.5 days), of which difference was not significant. But half of the patients in Ensure group discharged earlier than control group at 3 weeks after operation.
8. In Ensure group, 81% of patients were evaluated to be improved nutritional status according to assessment of nutritional index.
From these results it might be concluded that Ensure can be administered as an enteral supplemental diet to the patients of advanced gastric cancer received gastrectomy safely and effectively.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|